Company intelligence / Profile preview
Interface Biosciences
Palo Alto, California, United Statesinterface.bio ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Lead therapeutic program is a 44-amino peptide derived from Ruminoocccus gnavus with multifunctional properties including wound healing, inflammation reduction, and antibiotic activity against pathogens. Initial data shows stability and non-toxic nature, with in vivo studies planned to commence in January 2024[4].
- Therapeutic areas
- GastroenterologyDermatologyImmunology
- Modalities
- PeptidesNatural productsSactipeptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Interface Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interface Biosciences.